Medical Retina Fellowship

在NEI临床中心已经进行了许多医学视网膜协议。 许多是I期研究，而其他是筛选和评估以及治疗方案的研究。 这些为流行病学和临床应用司进行的试验和流行病学研究提供了患者筛查。 这些包括眼内分泌相关眼病研究（AREDS 2）的随访和AREDS 2随访，lucentis或avastin（抗VEGF疗法）用于治疗糖尿病性黄斑水肿，而Lucentis用于研究高速吲哚菁绿色血管造影术用于年龄相关性黄斑变性，用小胶质细胞抑制剂治疗糖尿病性视网膜病变和视网膜血管闭塞，治疗中心性浆液性视网膜病变，和老年性黄斑变性的遗传学研究。 我们也有一个生物银行协议，我们将收集DNA和血液的一些视网膜血管疾病。 我们还开始与NINDS合作评估阿尔茨海默病患者的眼底，并与NINDS合作评估HIV相关神经变性患者的HIV眼部发现。

A number of medical retinal protocols have been conducted at the NEI clinical center. Many are phase 1 studies while others are studies in the screening and evaluation and treatment protocol. These provide patients for screening for trials and epidemiologic studies conducted by the Division of Epidemiology and Clinical Applications. These include the followup of Age-Related Eye Disease Study (AREDS2) and AREDS2 follow-up, lucentis or avastin (anti-VEGF therapy) for treatment of diabetic macular edema, while lucentis for a study of high speed indocyanine green angiography for age-related macular degeneration, treatment with microglial inhibitors for diabetic retinopathy and retinovascular occlusions, treatments for central serous retinopathy, and genetic studies of age-related macular degeneration. We have also had a biobank protocol where we would collect DNA and blood for a number of retinovascular diseases. We are also beginning a collaboration with the NINDS on evaluating the fundus of patients with Alzheimer's disease and with NINDS on HIV ocular findings in those with HIV associated neurodegeneration.